<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">69456</article-id><article-id pub-id-type="doi">10.7554/eLife.69456</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Addressing shortfalls of laboratory HbA<sub>1c</sub> using a model that incorporates red cell lifespan</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-99852"><name><surname>Xu</surname><given-names>Yongjin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9446-8402</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-235521"><name><surname>Bergenstal</surname><given-names>Richard M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-235522"><name><surname>Dunn</surname><given-names>Timothy C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3487-2504</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" corresp="yes" id="author-234268"><name><surname>Ajjan</surname><given-names>Ramzi A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1636-3725</contrib-id><email>R.Ajjan@leeds.ac.uk</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><aff id="aff1"><label>1</label><institution>Abbott Diabetes Care</institution><addr-line><named-content content-type="city">Alameda</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>International Diabetes Center, Park Nicollet, HealthPartners</institution><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds</institution><addr-line><named-content content-type="city">Leeds</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Perry</surname><given-names>Rachel</given-names></name><role>Reviewing Editor</role><aff><institution>Yale</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Carrasco</surname><given-names>Nancy</given-names></name><role>Senior Editor</role><aff><institution>Vanderbilt University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>13</day><month>09</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e69456</elocation-id><history><date date-type="received" iso-8601-date="2021-04-15"><day>15</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-08-24"><day>24</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Xu et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Xu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-69456-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-69456-figures-v2.pdf"/><abstract><p>Laboratory HbA<sub>1c</sub> does not always predict diabetes complications and our aim was to establish a glycaemic measure that better reflects intracellular glucose exposure in organs susceptible to complications. Six months of continuous glucose monitoring data and concurrent laboratory HbA<sub>1c</sub> were evaluated from 51 type 1 diabetes (T1D) and 80 type 2 diabetes (T2D) patients. Red blood cell (RBC) lifespan was estimated using a kinetic model of glucose and HbA<sub>1c</sub>, allowing the calculation of person-specific adjusted HbA<sub>1c</sub> (aHbA<sub>1c</sub>). Median (IQR) RBC lifespan was 100 (86–102) and 100 (83–101) days in T1D and T2D, respectively. The median (IQR) absolute difference between aHbA<sub>1c</sub> and laboratory HbA<sub>1c</sub> was 3.9 (3.0–14.3) mmol/mol [0.4 (0.3–1.3%)] in T1D and 5.3 (4.1–22.5) mmol/mol [0.5 (0.4–2.0%)] in T2D. aHbA<sub>1c</sub> and laboratory HbA<sub>1c</sub> showed clinically relevant differences. This suggests that the widely used measurement of HbA<sub>1c</sub> can underestimate or overestimate diabetes complication risks, which may have future clinical implications.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>glycated haemoglobin</kwd><kwd>red cell lifespan</kwd><kwd>kinetic modelling</kwd><kwd>complications</kwd><kwd>cellular glucose uptake</kwd><kwd>continuous glucose monitoring</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011946</institution-id><institution>Abbott Diabetes Care</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Xu</surname><given-names>Yongjin</given-names></name><name><surname>Dunn</surname><given-names>Timothy C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The person-specific adjusted HbA<sub>1c</sub> addresses non-glycaemic variation in laboratory HbA<sub>1c</sub> due to red blood cell lifespan differences, potentially providing a better marker to predict diabetes complications and guide glycaemic management.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>High glucose exposure in specific organs (particularly eye, kidney, and nerve) is a critical factor for the development of diabetes complications (<xref ref-type="bibr" rid="bib20">Marcovecchio, 2017</xref>; <xref ref-type="bibr" rid="bib10">Giacco and Brownlee, 2010</xref>). Laboratory HbA<sub>1c</sub> is routinely used to assess glycaemic control, but studies report a disconnect between this glycaemic marker and diabetes complications in some individuals (<xref ref-type="bibr" rid="bib6">Cohen et al., 2003</xref>; <xref ref-type="bibr" rid="bib3">Bonora and Tuomilehto, 2011</xref>). The exact mechanisms for this are not always clear but, at least in some cases, likely related to inaccurate estimation of intracellular glucose exposure in the affected organs.</p><p>While raised intracellular glucose is responsible for diabetes complications (<xref ref-type="bibr" rid="bib10">Giacco and Brownlee, 2010</xref>; <xref ref-type="bibr" rid="bib5">Brownlee, 2005</xref>), extracellular hyperglycaemia selectively damages cells with limited ability to adjust cross-membrane glucose transport effectively (<xref ref-type="bibr" rid="bib5">Brownlee, 2005</xref>). HbA<sub>1c</sub> has been used as a biomarker for diabetes-related intracellular hyperglycaemia for two main reasons. First, the glycation reaction occurs within red blood cells (RBCs) and therefore HbA<sub>1c</sub> is modulated by intracellular glucose level. Second, RBCs do not have the capacity to adjust glucose transporter GLUT1 levels and thus are unable to modify glucose uptake, behaving similarly to cells that are selectively damaged by extracellular hyperglycaemia (<xref ref-type="bibr" rid="bib5">Brownlee, 2005</xref>). Therefore, under conditions of fixed RBC lifespan and glucose uptake, HbA<sub>1c</sub> mirrors intracellular glucose exposure in organs affected by diabetes complications. However, given the inter-individual variability in both glucose uptake and RBC lifespan (<xref ref-type="bibr" rid="bib7">Cohen et al., 2008</xref>; <xref ref-type="bibr" rid="bib16">Khera et al., 2008</xref>), laboratory HbA<sub>1c</sub> may not always reflect intracellular RBC glucose exposure. While variation in RBC glucose uptake is likely relevant to the risk of diabetes complications in susceptible organs, variation in red cell lifespan can affect haemoglobin glycation and HbA1c values, in turn compromising the accuracy of this glycaemic marker in predicting risk of complications. This explains the inability to clinically rely on laboratory HbA<sub>1c</sub> in those with haematological disorders characterised by abnormal RBC turnover (<xref ref-type="bibr" rid="bib1">American Diabetes Association, 2019</xref>) and represents a possible explanation for the apparent ‘disconnect’ between laboratory HbA<sub>1c</sub> and development of complications in some individuals with diabetes (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Individual red blood cell (RBC) lifespan can affect HbA<sub>1c</sub> and diabetes treatment.</title><p>In some individuals, laboratory HbA<sub>1c</sub> can be misleading and resulting in undertreatment, thus increasing the risk of complications, or overtreatment, predisposing to hypoglycaemia.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69456-fig1-v2.tif"/></fig><p>A kinetic model, which considers individual variations in both RBC turnover and glucose uptake, has been developed to explain the disconcordance of the glucose-HbA<sub>1c</sub> relationship on individual level (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>). The current work aims to extend this model by providing a way to normalise against RBC lifespan variation when individual RBC lifespan becomes available. We propose a new clinical marker, which we term adjusted HbA<sub>1c</sub> (aHbA<sub>1c</sub>), by adjusting laboratory HbA<sub>1c</sub> for a standard RBC lifespan of 106 days (<xref ref-type="bibr" rid="bib8">English and Lenters-Westra, 2018</xref>) (equivalent to RBC turnover rate of 0.94% per day). The new glyacemic marker, aHbA<sub>1c</sub>, is likely to be the most accurate marker of organ exposure to hyperglycaemia and risk of future diabetes-related complications.</p></sec><sec id="s2" sec-type="results"><title>Results</title><p>Of the 287 individuals in the original studies, 218 had predefined continuous glucose monitoring (CGM) coverage between at least two HbA<sub>1c</sub> measurements. Of these, 131 individuals had adequate continuous glucose data to estimate RBC lifespan and glucose uptake rate. The subject characteristics of this sub-cohort are presented in <xref ref-type="table" rid="table1">Table 1</xref>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Main characteristics of the cohort studied.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">N</th><th align="left" valign="bottom">131</th></tr></thead><tbody><tr><td align="left" valign="bottom">Age [years; mean ± SD (range)]</td><td align="char" char="plusmn" valign="bottom">53.5 ± 13.7 (18, 77)</td></tr><tr><td align="left" valign="bottom">Gender, male [number (percentage)]</td><td align="char" char="." valign="bottom">86 (66%)</td></tr><tr><td align="left" valign="bottom">T1D [number (percentage)]T2D [number (percentage)]BMI [kg/m<sup>2</sup>; mean ± SD (range)]</td><td align="char" char="." valign="bottom">51 (39%)80 (61%)29.8 ± 5.9 (18.8, 54.1)</td></tr><tr><td align="left" valign="bottom">Duration of diabetes (years)</td><td align="char" char="plusmn" valign="bottom">17.7 ± 8.7 (2, 46)</td></tr><tr><td align="left" valign="bottom">Hypoglycaemic therapy</td><td align="left" valign="bottom">Multiple daily injections of insulin</td></tr><tr><td align="left" colspan="2" valign="bottom">Data are presented as mean ± SD (min, max) or n (%)</td></tr></tbody></table></table-wrap><p>Mean (median, IQR) RBC lifespan was 94 (100, 86–102) days in those with T1D and 92 (100, 83–101) in those with T2D (<xref ref-type="fig" rid="fig2">Figure 2</xref>). In this cohort, the mean, median, IQR of the absolute difference between aHbA<sub>1c</sub> and laboratory HbA<sub>1c</sub> were 11.0, 3.9, 3.0–14.3 mmol/mol (1.0, 0.4, 0.3–1.3%) for T1D, and marginally higher at 15.1, 5.3, 4.1–22.5 mmol/mol (1.4, 0.5, 0.4–2.0%) for T2D subjects. As illustrated in the figure, those with the shorter RBC lifespan of 80 days showed around 22 mmol/mol (2%) lower laboratory HbA<sub>1c</sub> than aHbA<sub>1c</sub>. This may lead to underestimating intracellular glucose exposure in susceptible organs, in turn increasing the risk of complications. In contrast, those with RBC lifespan of 130 days demonstrated higher laboratory HbA<sub>1c</sub> than aHbA<sub>1c</sub>, which can give the impression of inadequate glycaemic control, leading to therapy escalation and predisposition to hypoglycaemia.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Distribution of red blood cell (RBC) lifespan for type 1 (n = 51) and type 2 (n = 80) diabetes and adjustment to laboratory HbA<sub>1c</sub> by RBC lifespan.</title><p>The number (percentage) of individuals having HbA<sub>1c</sub> adjustments &lt; 1 % (&lt;11 mmol/mol), 1–2% (11–22 mmol/mol), 2–3% (22–33 mmol/mol), and &gt;3% (&gt;33 mmol/mol) were 90 (68%), 21 (16%), 12 (9%), and 8 (6%), respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-69456-fig2-v2.tif"/></fig><p>To further put these results into clinical context, two subjects with an identical laboratory HbA<sub>1c</sub> of 63 mmol/mol (7.9%) but different RBC lifespans of 89 and 107 days, would have RBC-lifespan-adjusted aHbA<sub>1c</sub> values of 78 mmol/mol (9.3%) and 62 mmol/mol (7.8%), respectively, indicating different future risk of diabetes complications. Another two individuals with different laboratory HbA<sub>1c</sub> of 60 mmol/mol (7.6%) and 75 mmol/mol (9.0%), and corresponding RBC lifespans of 89 and 107 days, would have identical aHbA<sub>1c</sub> value of 74 mmol/mol (8.9%). This would place them at similar risk of diabetes complications, despite the significantly different laboratory HbA<sub>1c</sub> values. Generally, in individuals with RBC lifespan of approximately 93–123 days, aHbA<sub>1c</sub> and laboratory HbA<sub>1c</sub> showed relatively small differences (&lt;11 mmol/mol or 1% when laboratory HbA<sub>1c</sub> &lt; 64 mmol/mol or 8%). In this cohort, 90 (69%) subjects were within RBC lifespan range of 93–123 days, while 39 (30%) subjects had RBC lifespan below 93 days and 2 (1.5%) subjects above 123 days.</p></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Variation in RBC lifespan and glucose uptake between individuals can lead to different laboratory HbA<sub>1c</sub> despite similar hyperglycaemic exposure in the organs affected by diabetes complications. In order to individualise care and assess the personal risk of hyperglycaemic complications, laboratory HbA<sub>1c</sub> levels should be adjusted to account for variability in RBC turnover through our proposed aHbA<sub>1c</sub>. Without this adjustment, there is a risk of overestimating glucose levels that may cause hypoglycaemia through the unnecessary escalation of diabetes therapies, or alternatively, underestimation that may lead to undertreatment and subsequent high risk of complications. In addition, there are implications for the diagnosis of prediabetes and diabetes, as there may be misclassifications if the diagnosis is based solely on laboratory HbA<sub>1c</sub> levels due to variable RBC lifespan across individuals.</p><p>RBC removal by senescence and erythrocyte apoptosis are complex processes, which can be affected by the presence of hyperglycaemia and known to vary both within and across individuals (<xref ref-type="bibr" rid="bib18">Lang et al., 2012</xref>). In the meantime, potential differences in RBC glucose uptake (<xref ref-type="bibr" rid="bib16">Khera et al., 2008</xref>) can also affect the relationship between blood glucose and HbA<sub>1c</sub>. Several mathematical models (<xref ref-type="bibr" rid="bib19">Malka et al., 2016</xref>; <xref ref-type="bibr" rid="bib9">Fabris et al., 2020</xref>) have been developed to estimate laboratory HbA<sub>1c</sub> from glucose levels or time in range, emphasising the importance of this area. Accurate estimation of ‘clinically relevant HbA1c’ will allow each person with diabetes to have an individualised glycaemic target that ensures adequate treatment, thus reducing the risk of complications while minimising hypoglycaemic risk.</p><p>A unique feature of our model (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>) is the inclusion of individual-specific RBC lifespan and glycation rate in the calculations. A weakness of this model, however, is the absence of a direct measure of RBC lifespan, which remains an estimate based on a mathematical calculation. However, the ability of the model to reflect laboratory HbA<sub>1c</sub>, as we have previously shown, indicates a good level of accuracy at estimating RBC lifespan ( <xref ref-type="bibr" rid="bib24">Xu et al., 2021c</xref>). In addition, the method is far simpler than complex methods for estimating RBC lifespan through labelling experiments that are not suited for routine clinical practice (<xref ref-type="bibr" rid="bib7">Cohen et al., 2008</xref>). Future work may determine whether other measures, such as reticulocyte count or red cell distribution width (<xref ref-type="bibr" rid="bib4">Brodksy, 2021</xref>; <xref ref-type="bibr" rid="bib13">Kameyama et al., 2018</xref>; <xref ref-type="bibr" rid="bib14">Kameyama et al., 2020</xref>), can further be added to the model to further improve the accuracy of estimating RBC lifespan and this remains an area for future research.</p><p>Since aHbA<sub>1c</sub> reflects intracellular glucose exposure in RBCs, it is difficult to directly compare with extracellular glucose-derived glycaemic markers such as average glucose or time in range. As an intracellular marker, aHbA<sub>1c</sub> should correlate with intracellular glucose levels, therefore providing a potentially accurate measure of glucose exposure of organs susceptible to diabetes complications. We summarise the advantages and drawbacks of different methods that measure average glucose control in <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>.</p><p>Importantly, our study demonstrates that laboratory HbA<sub>1c</sub> does not necessarily reflect intracellular glucose exposure of organs prone to diabetes complications. However, future work is required to show that adjusted A<sub>1c</sub> is a better predictor of diabetes complications than laboratory HbA<sub>1c</sub>. Moreover, it is unclear whether the use of aHbA<sub>1c</sub> reduces the risk of hypoglycaemic complications as compared to reliance on laboratory HbA<sub>1c</sub>, and these remain areas for future research.</p><p>In conclusion, quantitative aHbA<sub>1c</sub>, derived from laboratory HbA<sub>1c</sub> and CGM readings, has the potential to more accurately assess glycaemic exposure of different organs, providing a safer and more effective glycaemic guide for the management of individuals with diabetes. Future testing in larger populations and different ethnic groups is required to further increase confidence in the model. This to be followed by large prospective clinical studies to test the relationship between aHbA<sub>1c</sub> and future microvascular/macrovascular diabetes complications as well as reducing the risk of hypoglycaemic exposure through avoidance of unnecessary therapy escalation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><p>CGM and laboratory HbA<sub>1c</sub> data from 139 type 1 (T1D) and 148 type 2 diabetes (T2D) patients, enrolled in two previous European clinical studies (<xref ref-type="bibr" rid="bib2">Bolinder et al., 2016</xref>; <xref ref-type="bibr" rid="bib11">Haak et al., 2017</xref>), were evaluated to calculate aHbA<sub>1c</sub> as detailed below. These studies were designed to evaluate the benefits of CGM in those with T1D and those with T2D using multiple daily injections of insulin. Both studies were conducted after appropriate ethical approval and participants gave written informed consent. A total of 6 months’ CGM data were collected using the sensor-based flash glucose monitoring system (FreeStyle Libre; Abbott Diabetes Care, Witney, UK), while HbA<sub>1c</sub> was measured by a central laboratory (ICON Laboratories, Dublin, Ireland) at 0, 3, and 6 months of the study. For T1D participants, the mean age was 44 years (range 18–70 years), 17 (33%) of whom were females. For T2D, the mean age was 59 years (range 33–77 years), 28 (35%) of whom were females.</p><p>Each subject had at least one data section consisting of two HbA<sub>1c</sub> measurements connected by CGM data. Since the kinetic parameters are more sensitive to the data sections with larger between-day glucose changes, the parameters were successfully estimated for those individuals with sufficient day-to-day glucose variability, as evidenced by the model fit of RBC life converging between 50 and 180 days. These individual RBC lifespans or turnover rates were calculated according to previous model (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>) that considers both RBC turnover rate and glucose uptake. Briefly, the model aligns laboratory HbA<sub>1c</sub> and the contemporaneous CGM-derived estimate of HbA<sub>1c</sub> under optimal values for RBC turnover and glucose uptake of each individual. Since there is no simple clinical assay for RBC turnover and glucose uptake, these RBC parameters are estimated using a numerical method such that differences between laboratory HbA<sub>1c</sub> and CGM-derived estimate are minimized. While the parameter identification method can be performed by repeated permutations across all reasonably possible values for RBC lifespan and uptake, our approach uses a far more efficient and reliable numerical method, as previously described (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>). Detailed model description and derivation are provided in Appendix 1. Deriving from the same model, we constructed aHbA<sub>1c</sub> (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>) that adjusts laboratory HbA<sub>1c</sub> for individual RBC turnover variation for potential clinical use.<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mrow><mml:mi>a</mml:mi><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>In an approximation, <inline-formula><mml:math id="inf1"><mml:mi>a</mml:mi><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mi> </mml:mi><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:math></inline-formula>, where <italic>HbA<sub>1c</sub></italic> is laboratory HbA<sub>1c</sub>, <italic>k<sub>age</sub></italic> is individual RBC turnover rate (%/day), <inline-formula><mml:math id="inf2"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> is standard RBC turnover rate (0.94%/day). HbA<sub>1c</sub> and aHbA<sub>1c</sub> are in NGSP unit and decimal values should be used. For example, 8% HbA<sub>1c</sub> should be applied as 0.08. <xref ref-type="disp-formula" rid="equ1">Equation 1</xref> for IFCC unit is available in Appendix 1.</p><p>Under the assumption of individually constant RBC life, the relationship between RBC turnover rate (<italic>k</italic><sub><italic>age</italic></sub>), RBC lifespan (<italic>L</italic><sub><italic>RBC</italic></sub>) and mean RBC age (<italic>MA</italic><sub><italic>RBC</italic></sub>) can be inter-converted using the simple formula: <inline-formula><mml:math id="inf3"><mml:mn>2</mml:mn><mml:mi>*</mml:mi><mml:mi>M</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>B</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>B</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> . Therefore, 0.94%/day standard RBC turnover rate is equivalent to 106 days of RBC life and 53 days of mean RBC age. Of note, the adjustment is not linear, decreasing RBC lifespan corresponds to more pronounced aHbA<sub>1c</sub> adjustment than a seemingly comparable increase in RBC lifespan. All calculations in this study were done with Python/SciPy (<xref ref-type="bibr" rid="bib21">Virtanen et al., 2020</xref>) software package.</p><p>Full derivation of the model is further provided in Appendix 1.</p></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>YX is an employee of Abbott Diabetes Care</p></fn><fn fn-type="COI-statement" id="conf2"><p>RMB has received research support, has acted as a consultant, or has been on the scientific advisory board for Abbott Diabetes Care, Ascensia, DexCom, Eli Lilly, Hygieia, Johnson &amp; Johnson, Medtronic, Merck, Novo Nordisk, Onduo, Roche, Sanofi and United Healthcare. RMB's employer, non-profit HealthPartners Institute, contracts for his services and no personal income goes to RMB.</p></fn><fn fn-type="COI-statement" id="conf3"><p>TCD is an employee of Abbott Diabetes Care</p></fn><fn fn-type="COI-statement" id="conf4"><p>RAA received no payment for this work but has had research support and/or Honoraria from Abbott Diabetes Care, NovoNordisk, Eli Lilly, Johnson &amp; Johnson, Boehringer Ingelheim, Bayer, Sanofi and AstraZeneca.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Supervision, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Formal analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing - original draft, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Data were used from two previously published clinical studies in Europe (reference 10 and 11). Both studies were conducted after appropriate ethical approval and participants gave written informed consent.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-69456-transrepform1-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Data file for figures have been provided.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was funded by Abbott Diabetes Care.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group><year iso-8601-date="2019">2019</year><article-title>6. Glycemic Targets: Standards of Medical Care in Diabetes-2019</article-title><source>Diabetes Care</source><volume>42</volume><fpage>S61</fpage><lpage>S70</lpage><pub-id pub-id-type="doi">10.2337/dc19-S006</pub-id><pub-id pub-id-type="pmid">30559232</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolinder</surname><given-names>J</given-names></name><name><surname>Antuna</surname><given-names>R</given-names></name><name><surname>Geelhoed-Duijvestijn</surname><given-names>P</given-names></name><name><surname>Kröger</surname><given-names>J</given-names></name><name><surname>Weitgasser</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel glucose-sensing technology and hypoglycaemia in Type 1 diabetes: A multicentre, non-masked, randomised controlled trial</article-title><source>Lancet</source><volume>388</volume><fpage>2254</fpage><lpage>2263</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31535-5</pub-id><pub-id pub-id-type="pmid">27634581</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonora</surname><given-names>E</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The pros and cons of diagnosing diabetes with A1C</article-title><source>Diabetes Care</source><volume>34</volume><fpage>S184</fpage><lpage>S190</lpage><pub-id pub-id-type="doi">10.2337/dc11-s216</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brodksy</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2021">2021</year><source>Diagnosis of Hemolytic Anemia in Adults</source><publisher-name>UpToDate</publisher-name></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brownlee</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The pathobiology of diabetic complications: A unifying mechanism</article-title><source>Diabetes</source><volume>54</volume><fpage>1615</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.2337/diabetes.54.6.1615</pub-id><pub-id pub-id-type="pmid">15919781</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RM</given-names></name><name><surname>Holmes</surname><given-names>YR</given-names></name><name><surname>Chenier</surname><given-names>TC</given-names></name><name><surname>Joiner</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Discordance between HbA1c <sub>a</sub>nd fructosamine: Evidence for a glycosylation gap and its relation to diabetic nephropathy</article-title><source>Diabetes Care</source><volume>26</volume><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.2337/diacare.26.1.163</pub-id><pub-id pub-id-type="pmid">12502674</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RM</given-names></name><name><surname>Franco</surname><given-names>RS</given-names></name><name><surname>Khera</surname><given-names>PK</given-names></name><name><surname>Smith</surname><given-names>EP</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><name><surname>Ciraolo</surname><given-names>PJ</given-names></name><name><surname>Palascak</surname><given-names>MB</given-names></name><name><surname>Joiner</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Red cell life span heterogeneity in hematologically normal people is sufficient to alter HBA1C</article-title><source>Blood</source><volume>112</volume><fpage>4284</fpage><lpage>4291</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-04-154112</pub-id><pub-id pub-id-type="pmid">18694998</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>English</surname><given-names>E</given-names></name><name><surname>Lenters-Westra</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>HbA1c method performance: The great success story of global standardization</article-title><source>Critical Reviews in Clinical Laboratory Sciences</source><volume>55</volume><fpage>408</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1080/10408363.2018.1480591</pub-id><pub-id pub-id-type="pmid">30001673</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabris</surname><given-names>C</given-names></name><name><surname>Heinemann</surname><given-names>L</given-names></name><name><surname>Beck</surname><given-names>RW</given-names></name><name><surname>Cobelli</surname><given-names>C</given-names></name><name><surname>Kovatchev</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Estimation of Hemoglobin A1c from Continuous Glucose Monitoring Data in Individuals with Type 1 Diabetes: Is Time In Range All We Need?</article-title><source>Diabetes Technology &amp; Therapeutics</source><volume>22</volume><fpage>501</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1089/dia.2020.0236</pub-id><pub-id pub-id-type="pmid">32459124</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giacco</surname><given-names>F</given-names></name><name><surname>Brownlee</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Oxidative stress and diabetic complications</article-title><source>Circulation Research</source><volume>107</volume><fpage>1058</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.223545</pub-id><pub-id pub-id-type="pmid">21030723</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haak</surname><given-names>T</given-names></name><name><surname>Hanaire</surname><given-names>H</given-names></name><name><surname>Ajjan</surname><given-names>RA</given-names></name><name><surname>Hermanns</surname><given-names>N</given-names></name><name><surname>Riveline</surname><given-names>JP</given-names></name><name><surname>Rayman</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial</article-title><source>Diabetes Ther</source><volume>8</volume><fpage>55</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1007/s13300-016-0223-6</pub-id><pub-id pub-id-type="pmid">28000140</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>PJ</given-names></name><name><surname>Bunn</surname><given-names>HF</given-names></name></person-group><year iso-8601-date="1981">1981</year><article-title>Kinetic analysis of the nonenzymatic glycosylation of hemoglobin</article-title><source>Journal of Biological Chemistry</source><volume>256</volume><fpage>5204</fpage><lpage>5208</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(19)69387-7</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kameyama</surname><given-names>M</given-names></name><name><surname>Takeuchi</surname><given-names>S</given-names></name><name><surname>Ishii</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Steady-state relationship between average glucose, HbA1c and RBC lifespan</article-title><source>Journal of Theoretical Biology</source><volume>447</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.jtbi.2018.03.023</pub-id><pub-id pub-id-type="pmid">29559230</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kameyama</surname><given-names>M</given-names></name><name><surname>Koga</surname><given-names>M</given-names></name><name><surname>Okumiya</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A novel method for calculating mean erythrocyte age using erythrocyte creatine</article-title><source>Aging</source><volume>12</volume><fpage>8702</fpage><lpage>8709</lpage><pub-id pub-id-type="doi">10.18632/aging.103193</pub-id><pub-id pub-id-type="pmid">32392179</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kameyama</surname><given-names>M</given-names></name><name><surname>Okumiya</surname><given-names>T</given-names></name><name><surname>Tokuhiro</surname><given-names>S</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name><name><surname>Matsui</surname><given-names>H</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Iwasaka</surname><given-names>T</given-names></name><name><surname>Hiratani</surname><given-names>K</given-names></name><name><surname>Koga</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Estimation of the hemoglobin glycation rate constant</article-title><source>Scientific Reports</source><volume>11</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/s41598-020-80024-7</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khera</surname><given-names>PK</given-names></name><name><surname>Joiner</surname><given-names>CH</given-names></name><name><surname>Carruthers</surname><given-names>A</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><name><surname>Smith</surname><given-names>EP</given-names></name><name><surname>Franco</surname><given-names>RS</given-names></name><name><surname>Holmes</surname><given-names>YR</given-names></name><name><surname>Cohen</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation</article-title><source>Diabetes</source><volume>57</volume><fpage>2445</fpage><lpage>2452</lpage><pub-id pub-id-type="doi">10.2337/db07-1820</pub-id><pub-id pub-id-type="pmid">18591386</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ladyzynski</surname><given-names>P</given-names></name><name><surname>Wójcicki</surname><given-names>JM</given-names></name><name><surname>Bąk</surname><given-names>MI</given-names></name><name><surname>Sabalińska</surname><given-names>S</given-names></name><name><surname>Kawiak</surname><given-names>J</given-names></name><name><surname>Foltyński</surname><given-names>P</given-names></name><name><surname>Krzymień</surname><given-names>J</given-names></name><name><surname>Karnafel</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hemoglobin glycation rate constant in non-diabetic individuals</article-title><source>Annals of Biomedical Engineering</source><volume>39</volume><fpage>2721</fpage><lpage>2734</lpage><pub-id pub-id-type="doi">10.1007/s10439-011-0366-6</pub-id><pub-id pub-id-type="pmid">21796500</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lang</surname><given-names>F</given-names></name><name><surname>Lang</surname><given-names>E</given-names></name><name><surname>Foller</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Physiology and pathophysiology of eryptosis</article-title><source>Transfusion Medicine and Hemotherapy</source><volume>39</volume><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1159/000342534</pub-id><pub-id pub-id-type="pmid">23801921</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malka</surname><given-names>R</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Higgins</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring</article-title><source>Sci Transl Med</source><volume>8</volume><elocation-id>359ra130</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf9304</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcovecchio</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Complications of acute and chronic hyperglycemia</article-title><source>US Endocrinology</source><volume>13</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.17925/USE.2017.13.01.17</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virtanen</surname><given-names>P</given-names></name><name><surname>Gommers</surname><given-names>R</given-names></name><name><surname>Oliphant</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SciPy 1.0: Fundamental Algorithms for Scientific Computing in Python</article-title><source>Nature Methods</source><volume>17</volume><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0686-2</pub-id><pub-id pub-id-type="pmid">32015543</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Dunn</surname><given-names>TC</given-names></name><name><surname>Ajjan</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>A kinetic model for glucose levels and hemoglobin A1C provides a novel tool for individualized diabetes management</article-title><source>Journal of Diabetes Science and Technology</source><volume>15</volume><fpage>294</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1177/1932296819897613</pub-id><pub-id pub-id-type="pmid">31910672</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Grimsmann</surname><given-names>JM</given-names></name><name><surname>Karges</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Personal Glycation Factors and Calculated Hemoglobin A1c for Diabetes Management: Real-World Data from the Diabetes Prospective Follow-up (DPV) Registry</article-title><source>Diabetes Technology &amp; Therapeutics</source><volume>23</volume><fpage>452</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1089/dia.2020.0553</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hirota</surname><given-names>Y</given-names></name><name><surname>Ajjan</surname><given-names>RA</given-names></name><name><surname>Yamamoto</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021c</year><article-title>Accurate prediction of HbA1c by continuous glucose monitoring using a kinetic model with patient-specific parameters for red blood cell lifespan and glucose uptake</article-title><source>Diabetes and Vascular Disease Research</source><volume>12</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1177/14791641211013734</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec id="s8" sec-type="appendix"><title>Derivation of <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref>: kinetic model review</title><p>The previously published kinetic model (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>) for glucose and HbA<sub>1c</sub> relationship led to <xref ref-type="disp-formula" rid="equ1">Equation (1)</xref>, shown in the main text. We further describe here the derivation of the model for the convenience of the reader. We also cover how the model can be used to estimate personal kinetic parameters for RBC glucose uptake and RBC turnover rate.</p><p>Our model assumes: (1) first-order dependencies for concentrations of both haemoglobin in RBCs and intracellular glucose; (2) newly generated RBCs have a negligible amount of glycated haemoglobin; (3) RBCs have a fixed life, so that they are generated constantly and eliminated from circulation when they reach an age that is individual-specific.</p><p>The rate of change in glycated and non-glycated haemoglobin in RBCs can be modelled by differential equations:<disp-formula id="equ2"><label>(a1)</label><mml:math id="m2"><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mi mathvariant="bold-italic">G</mml:mi></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mi mathvariant="bold-italic">t</mml:mi><mml:msub><mml:mrow><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">g</mml:mi></mml:mrow></mml:msub><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mi mathvariant="bold-italic">I</mml:mi></mml:mrow></mml:mfenced><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi></mml:mrow></mml:mfenced><mml:mo>-</mml:mo><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mn>1</mml:mn><mml:mi mathvariant="bold-italic">c</mml:mi></mml:math></disp-formula><disp-formula id="equ3"><label>(a2)</label><mml:math id="m3"><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mo>[</mml:mo><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mo>]</mml:mo><mml:mo>/</mml:mo><mml:mi mathvariant="bold-italic">d</mml:mi><mml:mi mathvariant="bold-italic">t</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">g</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi><mml:mi mathvariant="bold-italic">n</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mo>-</mml:mo><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mn>1</mml:mn><mml:mi mathvariant="bold-italic">c</mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">g</mml:mi></mml:mrow></mml:msub><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mi mathvariant="bold-italic">I</mml:mi></mml:mrow></mml:mfenced><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi></mml:mrow></mml:mfenced></mml:math></disp-formula></p><p>[<italic>HbG</italic>] and [<italic>Hb</italic>] are the concentrations of glycated and non-glycated haemoglobin, respectively, while [<italic>GI</italic>] is intracellular glucose concentration. The <italic>k<sub>g</sub></italic> is the rate constant of haemoglobin glycation reaction in unit of (concentration*time)<sup>–1</sup>, with a reported value of about 0.0019 dL/mg/day (<xref ref-type="bibr" rid="bib12">Higgins and Bunn, 1981</xref>). <italic>C</italic> is the total haemoglobin concentration <italic>C =</italic> [<italic>Hb</italic>] <italic>+</italic> [<italic>HbG</italic>]<italic>. A<sub>1c</sub></italic> is the fraction of glycated haemoglobin [<italic>HbG</italic>]/<italic>C</italic>, <italic>r</italic> is RBC removal rate in unit of concentration/time, <italic>α</italic> is a coefficient used to scale HbA<sub>1c</sub> to the fraction of glycated haemoglobin to be removed (has no units of measurement).</p><p>The glucose transporters on RBC membranes (GLUT1) follows Michaelis-Menten kinetic with a universal <italic>K<sub>M</sub></italic> approximately 26 mM (<xref ref-type="bibr" rid="bib17">Ladyzynski et al., 2011</xref>). Intracellular glucose can be modelled with <inline-formula><mml:math id="inf4"><mml:mi>d</mml:mi><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mi>I</mml:mi><mml:mo>]</mml:mo><mml:mo>/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="normal">*</mml:mi><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mo>]</mml:mo><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mo>]</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>)</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="normal">*</mml:mi><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mi>I</mml:mi><mml:mo>]</mml:mo></mml:math></inline-formula>, where [<italic>G</italic>] is the extracellular glucose concentration and <italic>k<sub>c</sub></italic> is the rate of glucose consumption within RBCs. The maximum rate <italic>V<sub>max</sub></italic> should be proportional to the GLUT1 level on the membrane and we assume both <italic>k</italic><sub><italic>c</italic></sub> and <italic>V</italic><sub><italic>max</italic></sub> can vary between individuals. Since this process is fast, we use the equilibrium condition:<disp-formula id="equ4"><label>(a3)</label><mml:math id="m4"><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>G</mml:mi><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mi>c</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mi>g</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mi>g</mml:mi></mml:msub></mml:mfrac><mml:mi>g</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mi>g</mml:mi></mml:msub></mml:mfrac><mml:mfrac><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub><mml:mo>∗</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>M</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mi>G</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>where <inline-formula><mml:math id="inf5"><mml:mi>g</mml:mi><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mo>]</mml:mo><mml:mo>)</mml:mo><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mo>]</mml:mo><mml:mo>)</mml:mo></mml:math></inline-formula> and <inline-formula><mml:math id="inf6"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula>.</p><p>By definition, HbA<sub>1c</sub> is the fraction of glycated haemoglobin found in RBCs:<disp-formula id="equ5"><mml:math id="m5"><mml:mrow><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>C</mml:mi><mml:mo>−</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>C</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>In steady state, <inline-formula><mml:math id="inf7"><mml:mi>d</mml:mi><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mi>d</mml:mi><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>G</mml:mi></mml:mrow></mml:mfenced><mml:mo>/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, <xref ref-type="disp-formula" rid="equ2">Equation (a1)</xref> becomes<disp-formula id="equ6"><mml:math id="m6"><mml:mrow><mml:mi>C</mml:mi><mml:mo>∗</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>α</mml:mi><mml:mo>∗</mml:mo><mml:mi>r</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>G</mml:mi><mml:mi>I</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p>Combining with <xref ref-type="disp-formula" rid="equ4">Equation (a3)</xref>:<disp-formula id="equ7"><label>(a4)</label><mml:math id="m7"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">C</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mi mathvariant="bold-italic">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">g</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="bold">*</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">V</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">m</mml:mi><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mi mathvariant="bold-italic">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">M</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mi mathvariant="bold-italic">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mi mathvariant="bold-italic">G</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">g</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>By combining all parameters associated with cross-membrane glucose transport and glycation from the right-hand side of <xref ref-type="disp-formula" rid="equ7">Equation (a4)</xref>, we define the composite glycation rate constant</p><p><inline-formula><mml:math id="inf8"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula>, where <italic>k<sub>g</sub></italic> and <italic>K</italic><sub><italic>M</italic></sub> are universal constants for the non-enzymatic haemoglobin glycation reaction and glucose affinity to GLUT1, respectively. Therefore, <italic>k<sub>gly</sub></italic> can vary between individuals depending on <italic>k<sub>c</sub></italic> and <italic>V<sub>max</sub></italic>.</p><p>We attribute the rest of the parameters to RBC turnover <italic>k<sub>age</sub></italic> = <italic>α*r/C</italic>, which leads to the definition of the apparent glycation parameter <italic>K</italic>:<disp-formula id="equ8"><label>(a5)</label><mml:math id="m8"><mml:mi mathvariant="bold-italic">K</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">g</mml:mi><mml:mi mathvariant="bold-italic">l</mml:mi><mml:mi mathvariant="bold-italic">y</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">a</mml:mi><mml:mi mathvariant="bold-italic">g</mml:mi><mml:mi mathvariant="bold-italic">e</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>[</mml:mo><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mi mathvariant="bold-italic">G</mml:mi><mml:mo>]</mml:mo><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:mi mathvariant="bold-italic">g</mml:mi><mml:mi mathvariant="bold-italic">*</mml:mi><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi mathvariant="bold-italic">H</mml:mi><mml:mi mathvariant="bold-italic">b</mml:mi></mml:mrow></mml:mfenced><mml:mo>)</mml:mo></mml:math></disp-formula></p><p>Under a hypothetical steady state of constant glucose level, HbA<sub>1c</sub> should reach an equilibrium level, which is the ‘equilibrium HbA<sub>1c</sub>’ or <italic>EA</italic>. Since <italic>C=</italic>[<italic>HbG</italic>]<italic>+</italic>[<italic>Hb</italic>], <xref ref-type="disp-formula" rid="equ8">Equation (a5)</xref> can be re-written to <inline-formula><mml:math id="inf9"><mml:mi>K</mml:mi><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mi>C</mml:mi><mml:mo>-</mml:mo><mml:mo>[</mml:mo><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mo>]</mml:mo><mml:mo>)</mml:mo><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:mi>g</mml:mi><mml:mi>*</mml:mi><mml:mo>[</mml:mo><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mo>]</mml:mo><mml:mo>)</mml:mo></mml:math></inline-formula>. Applying the definition <italic>HbA</italic><sub><italic>1c</italic></sub> <italic>= HbG</italic>/<italic>C</italic> = (<italic>C−</italic>[<italic>Hb</italic>])/<italic>C</italic>, we have:<disp-formula id="equ9"><label>(a6)</label><mml:math id="m9"><mml:mi mathvariant="bold-italic">E</mml:mi><mml:mi mathvariant="bold-italic">A</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="bold-italic">g</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold-italic">K</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi mathvariant="bold-italic"> </mml:mi><mml:mi mathvariant="bold-italic">g</mml:mi></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>This relationship approximates the average glucose and HbA<sub>1c</sub> for an individual with a stable day-to-day glucose profile.</p><p>From <xref ref-type="disp-formula" rid="equ4">Equation (a3)</xref>: <inline-formula><mml:math id="inf10"><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>G</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>V</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>c</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>g</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mi>g</mml:mi></mml:math></inline-formula>, and substituting into <xref ref-type="disp-formula" rid="equ9">Equation (a6)</xref> gives:<disp-formula id="equ10"><label>(a7)</label><mml:math id="m10"><mml:mo>[</mml:mo><mml:mi>G</mml:mi><mml:mi>I</mml:mi><mml:mo>]</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:mi>E</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi> </mml:mi><mml:mi>E</mml:mi><mml:mi>A</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Imaging two individuals who have identical intracellular glucose level <inline-formula><mml:math id="inf11"><mml:msub><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>G</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:mi>G</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:math></inline-formula> , one with <inline-formula><mml:math id="inf12"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and the other with reference <inline-formula><mml:math id="inf13"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> . The relationship of their equilibrium HbA<sub>1c</sub> values is:<disp-formula id="equ11"><mml:math id="m11"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi> </mml:mi><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup><mml:mi>*</mml:mi><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi> </mml:mi><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>Again, <italic>k<sub>g</sub></italic> is the universal composite rate constant for glucose haemoglobin composite reaction. Simplifying this equation we have:<disp-formula id="equ12"><mml:math id="m12"><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>In a steady state, <inline-formula><mml:math id="inf14"><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> is the HbA<sub>1c</sub> under RBC turnover rate of <inline-formula><mml:math id="inf15"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . The <inline-formula><mml:math id="inf16"><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:math></inline-formula> is the HbA<sub>1c</sub> under the same intracellular glucose level, when RBC turnover rate is a reference value of <inline-formula><mml:math id="inf17"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> . Therefore, if we were to compare intracellular glucose exposure, steady-state HbA<sub>1c</sub> should be adjusted to a reference RBC turnover rate, which lead to the aHbA<sub>1c</sub> in <xref ref-type="disp-formula" rid="equ2">Equation (a1)</xref> by replacing <inline-formula><mml:math id="inf18"><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:math></inline-formula> with aHbA<sub>1c</sub> and <inline-formula><mml:math id="inf19"><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula> with HbA<sub>1c</sub>:<disp-formula id="equ13"><label>(1)</label><mml:math id="m13"><mml:mi>a</mml:mi><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mrow></mml:mfrac><mml:mi> </mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p><p>To simplify the above, an approximation to <xref ref-type="disp-formula" rid="equ2">Equation (a1)</xref> is <inline-formula><mml:math id="inf20"><mml:mi>a</mml:mi><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mi> </mml:mi><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mi> </mml:mi><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:math></inline-formula>. Note that <inline-formula><mml:math id="inf21"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>B</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>B</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>B</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>B</mml:mi><mml:mi>C</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> , where <italic>M</italic><sub><italic>RBC</italic></sub> is the mean RBC age and <italic>L</italic><sub><italic>RBC</italic></sub> is the RBC lifespan.</p><p>The HbA<sub>1c</sub> and aHbA<sub>1c</sub> take NGSP unit in decimal form by default. For example, the decimal form of HbA<sub>1c</sub> of 8% is 0.08. The unit for <inline-formula><mml:math id="inf22"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="inf23"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> should be %/day.</p><p>When IFCC unit (mmol/mol) is used for HbA<sub>1c</sub> and aHbA<sub>1c</sub>, <xref ref-type="disp-formula" rid="equ2">Equation (a1)</xref> becomes:<disp-formula id="equ14"><label>(2)</label><mml:math id="m14"><mml:mi>a</mml:mi><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1092.9</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mn>0.0915</mml:mn><mml:mi>*</mml:mi><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mn>2.15</mml:mn></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>-</mml:mo><mml:mn>23.5</mml:mn></mml:math></disp-formula></p></sec><sec id="s9" sec-type="appendix"><title>Estimations of <italic>k</italic><sub><italic>gly</italic></sub> and <italic>k</italic><sub><italic>age</italic></sub> from glucose and HbA<sub>1c</sub> data and prospective validation: kinetic model review</title><p>Our previous publication (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>) gave the following relationship by solving the differential <xref ref-type="disp-formula" rid="equ2">Equation (a1)</xref>:<disp-formula id="equ15"><label>(a8)</label><mml:math id="m15"><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>E</mml:mi><mml:mi>A</mml:mi><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:mi>E</mml:mi><mml:mi>A</mml:mi><mml:mo>)</mml:mo><mml:msup><mml:mrow><mml:mo>⋅</mml:mo><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:math></disp-formula></p><p><xref ref-type="disp-formula" rid="equ15">Equation (a8)</xref> is suitable for a short time interval. For a longer time period, a recursive form is required:<disp-formula id="equ16"><label>(a9)</label><mml:math id="m16"><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>E</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>+</mml:mo><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>z</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi>E</mml:mi><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mrow><mml:msubsup><mml:mo>∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:msubsup><mml:mo>∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>z</mml:mi></mml:mrow></mml:msubsup><mml:mrow><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula></p><p><xref ref-type="disp-formula" rid="equ16">Equation (a9)</xref> describes HbA<sub>1c</sub> change from time 0 to time <italic>z</italic>. <italic>A</italic><sub><italic>1c0</italic></sub> and <italic>A</italic><sub><italic>1cz</italic></sub> are the starting and ending HbA<sub>1c</sub> values. The time period is split into <italic>z</italic> time intervals with lengths of <italic>t<sub>i</sub></italic> (<italic>i =</italic> 1,2,3, …, <italic>z</italic>), where <inline-formula><mml:math id="inf24"><mml:msub><mml:mrow><mml:mi> </mml:mi><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi><mml:mi>l</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="inf25"><mml:mi>E</mml:mi><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi> </mml:mi><mml:msub><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></inline-formula> , and <inline-formula><mml:math id="inf26"><mml:msub><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> can be calculated from the average glucose (<italic>AG</italic>) in the time interval <inline-formula><mml:math id="inf27"><mml:msub><mml:mrow><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mi>*</mml:mi><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>/</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>M</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">G</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="normal"> </mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula>.</p><p>The value <italic>A</italic><sub><italic>1cz</italic></sub> is equivalent to calculated HbA<sub>1c</sub> (cHbA<sub>1c</sub>) at the end of time interval <italic>t<sub>z</sub></italic>. While shorter time intervals – such as 4–6 hr – are expected to produce better results, we have shown that a time interval of 24 hr has produced acceptable performance (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>). <xref ref-type="disp-formula" rid="equ16">Equation (a9)</xref> is central to our kinetic model. To estimate personal parameters <italic>k<sub>gly</sub></italic> and <italic>k<sub>age</sub></italic>, one or more data sections are needed, where a data section contains two HbA<sub>1c</sub> measurements, one at the start of the time period and one at the end, with frequent (i.e. every 15 min) glucose levels in-between. The optimised individual <italic>k<sub>gly</sub></italic> and <italic>k<sub>age</sub></italic> pair should best align the HbA<sub>1c</sub> and cHbA<sub>1c</sub>, minimising the preferred error function, such as mean difference or sum-squared difference.</p><p>Once an individual’s <italic>k<sub>gly</sub></italic> and <italic>k<sub>age</sub></italic> pair are available, <xref ref-type="disp-formula" rid="equ16">Equation (a9)</xref> is used to project future HbA<sub>1c</sub> if provided frequent glucose measurements. Therefore, prospective model validation is possible when multiple data sections are available, such that one or more can be held out of the parameter estimation to be used for prospective evaluation. <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref> summarises results (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>; <xref ref-type="bibr" rid="bib24">Xu et al., 2021c</xref>; <xref ref-type="bibr" rid="bib23">Xu et al., 2021b</xref>) when all but the last data section is used to determine the individual <italic>k<sub>gly</sub></italic> and <italic>k<sub>age</sub></italic> pairs, and the held-out final data section is used for evaluation. The agreement between the last HbA<sub>1c</sub> and cHbA<sub>1c</sub> is compared to the agreement between the last HbA<sub>1c</sub> and the glucose management indicator (GMI) (<xref ref-type="bibr" rid="bib22">Xu et al., 2021a</xref>; <xref ref-type="bibr" rid="bib24">Xu et al., 2021c</xref>; <xref ref-type="bibr" rid="bib23">Xu et al., 2021b</xref>). These studies demonstrated the superior accuracy of the kinetic model compared to the existing GMI method.</p><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Summary of kinetic model validation studies.</title><p>The mean absolute deviation differences between calculated HbA<sub>1c</sub> (cHbA<sub>1c</sub>) and glucose management indicator (GMI) are statically significant with p &lt; 0.0001.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" valign="top">Study</th><th align="left" colspan="2" valign="top">T1D SAP <sup>[22]</sup></th><th align="left" colspan="2" valign="top">DPV T1D <sup>[23]</sup></th><th align="left" colspan="2" valign="top">Replace/mpact <sup>[9]</sup></th></tr></thead><tbody><tr><td align="left" colspan="2" valign="top">Country</td><td align="left" colspan="2" valign="top">Japan</td><td align="left" colspan="2" valign="top">Germany</td><td align="left" colspan="2" valign="top">Europe</td></tr><tr><td align="left" colspan="2" valign="top">Subject count (male)</td><td align="char" char="." colspan="2" valign="top">51 (14)</td><td align="char" char="." colspan="2" valign="top">352 (171)</td><td align="char" char="." colspan="2" valign="top">120 (79) [TID 54 (37), T2D 66 (42)]</td></tr><tr><td align="left" colspan="2" valign="top">Age median (range)</td><td align="char" char="." colspan="2" valign="top">42 (6–73)</td><td align="char" char="." colspan="2" valign="top">12.5 (3–19)</td><td align="char" char="." colspan="2" valign="top">52 (18–77)</td></tr><tr><td align="left" colspan="2" valign="top">HbA<sub>1c</sub> test</td><td align="left" colspan="2" valign="top">Central lab</td><td align="left" colspan="2" valign="top">POC+ central lab</td><td align="left" colspan="2" valign="top">Central lab</td></tr><tr><td align="left" colspan="2" valign="top">CGM device</td><td align="left" colspan="2" valign="top">Medtronic</td><td align="left" colspan="2" valign="top">Abbott</td><td align="left" colspan="2" valign="top">Abbott</td></tr><tr><td align="left" colspan="2" valign="top">Method</td><td align="left" valign="top">cHbA<sub>1c</sub></td><td align="left" valign="top">GMI (14-day AG)</td><td align="left" valign="top">cHbA<sub>1c</sub></td><td align="left" valign="top">GMI (14-day AG)</td><td align="left" valign="top">cHbA<sub>1c</sub></td><td align="left" valign="top">GMI (14-day AG)</td></tr><tr><td align="left" rowspan="3" valign="top">Abs. dev.% (mmol/mol)</td><td align="left" valign="top">Mean</td><td align="char" char="." valign="top">0.11 (1.2)</td><td align="char" char="." valign="top">0.47 (5.1)</td><td align="char" char="." valign="top">0.32 (3.5)</td><td align="char" char="." valign="top">0.57 (6.2)</td><td align="char" char="." valign="top">0.31 (3.4)</td><td align="char" char="." valign="top">0.66 (7.2)</td></tr><tr><td align="left" valign="top">SD</td><td align="char" char="." valign="top">0.06 (0.7)</td><td align="char" char="." valign="top">0.46 (5.0)</td><td align="char" char="." valign="top">0.28 (3.0)</td><td align="char" char="." valign="top">0.55 (6.0)</td><td align="char" char="." valign="top">0.22 (2.4)</td><td align="char" char="." valign="top">0.46 (5.0)</td></tr><tr><td align="left" valign="top">Median</td><td align="char" char="." valign="top">0.10 (1.1)</td><td align="char" char="." valign="top">0.36 (3.9)</td><td align="char" char="." valign="top">0.26 (2.8)</td><td align="char" char="." valign="top">0.46 (5.0)</td><td align="char" char="." valign="top">0.27 (3.0)</td><td align="char" char="." valign="top">0.5 (5.5)</td></tr><tr><td align="left" colspan="2" valign="top">Average bias% (mmol/mol)</td><td align="char" char="." valign="top">0 (0)</td><td align="char" char="." valign="top">–0.3 (–3.3)</td><td align="char" char="." valign="top">0 (0)</td><td align="char" char="." valign="top">0.4 (4.4)</td><td align="char" char="." valign="top">0 (0)</td><td align="char" char="." valign="top">–0.6 (–6.6)</td></tr><tr><td align="left" colspan="2" valign="top"><italic>R</italic><sup>2</sup></td><td align="char" char="." valign="top">0.91</td><td align="char" char="." valign="top">0.65</td><td align="char" char="." valign="top">0.79</td><td align="char" char="." valign="top">0.52</td><td align="char" char="." valign="top">0.88</td><td align="char" char="." valign="top">0.63</td></tr></tbody></table></table-wrap></sec><sec id="s10" sec-type="appendix"><title>Glycaemic marker comparisons</title><p>Given the importance of intracellular glucose level in diabetes management. We provide following table to compare the intracellular aspects of some frequently used glycaemic markers.</p><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Main characteristics of markers assessing average glycaemic control.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" valign="bottom"/><th align="left" valign="bottom">Intracellular (I) or extracellular (E) glucose</th><th align="left" valign="bottom">Affected by mean red blood cell (RBC) lifespan</th><th align="left" valign="bottom">Advantages</th><th align="left" valign="bottom">Disadvantages</th></tr></thead><tbody><tr><td align="left" rowspan="2" valign="bottom">CGM-derived</td><td align="left" valign="bottom">Average glucose</td><td align="left" rowspan="2" valign="bottom">E</td><td align="left" rowspan="2" valign="bottom">No</td><td align="left" rowspan="3" valign="bottom"><list list-type="bullet"><list-item><p>Can reflect both long- (weeks/months) and short-term (minutes, hours) glucose control</p></list-item></list></td><td align="left" rowspan="4" valign="bottom"><list list-type="bullet"><list-item><p>Extracellular measurements</p></list-item><list-item><p>Lack of large-scale longitudinal studies demonstrating a direct association with long-term complications</p></list-item></list></td></tr><tr><td align="left" valign="bottom">Time in range</td></tr><tr><td align="left" colspan="2" valign="bottom">Average fasting plasma glucose</td><td align="left" valign="bottom">E</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" colspan="2" valign="bottom">Glycated albumin</td><td align="left" valign="bottom">E</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Mid-term (weeks) average glucose</p></list-item></list></td></tr><tr><td align="left" colspan="2" valign="bottom">HbA<sub>1c</sub></td><td align="left" valign="bottom">I</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Long-term (months) intracellular average glucose exposure</p></list-item><list-item><p>Longitudinal studies demonstrating associations with long-term complications</p></list-item></list></td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Affected by variation in RBC lifespan</p></list-item><list-item><p>Lacks accuracy in the presence of other conditions (anaemias, renal failure, haemoglobin variants, etc.)</p></list-item></list></td></tr><tr><td align="left" colspan="2" valign="bottom">Adjusted HbA<sub>1c</sub></td><td align="left" valign="bottom">I</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Long-term intracellular average glucose</p></list-item><list-item><p>Exposure normalised for RBC lifespan, providing a personalised glycaemic marker</p></list-item></list></td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Requires RBC lifespan determination</p></list-item><list-item><p>Longitudinal studies linking with outcome are lacking</p></list-item></list></td></tr><tr><td align="left" colspan="2" valign="bottom">Intracellular glucose</td><td align="left" valign="bottom">I</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>Reflects both long- and short-term intracellular glucose control</p></list-item></list></td><td align="left" valign="bottom"><list list-type="bullet"><list-item><p>No direct measurement available</p></list-item><list-item><p>Requires RBC glucose uptake rate determination (<xref ref-type="bibr" rid="bib17">Ladyzynski et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">Kameyama et al., 2021</xref>), which is not feasible in routine clinical practice</p></list-item></list></td></tr></tbody></table></table-wrap></sec></app></app-group></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69456.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Perry</surname><given-names>Rachel</given-names></name><role>Reviewing Editor</role><aff><institution>Yale</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Szadkowska</surname><given-names>Agnieszka</given-names></name><role>Reviewer</role></contrib><contrib contrib-type="reviewer"><name><surname>Kameyama</surname><given-names>Masashi</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This paper will be of interest to clinicians who provide care for persons with diabetes, educators who prepare these clinicians, as well as persons with diabetes who wish to be proactive participants in their own care. The calculation for an adjusted Hemoglobin A1c proposed by the authors can correct for individual red blood cell lifespan variations that can lead to misrepresentation of glycemic control. With the addition of a data-driven comparison to other means of assessing glycemic control, the adjusted HbA1c has the potential to improve care and subsequently decrease morbidity and mortality for persons with diabetes.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;HbA<sub>1c</sub> and Red Blood Cell Lifespan: Addressing shortfalls of the laboratory measure&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Nancy Carrasco as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Agnieszka Szadkowska (Reviewer #2); Masashi Kameyama (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) A more complete description of the derivation of the model – more detail is required as to how the computations were done.</p><p>2) A comparison to other methods of assessing glycemic control (CGM, A1c). While assessment of how the authors' model predicts complications will not be required, a comparison (or at the very least, detailed discussion) of how it can compare to standard means of assessing glycemic control is necessary.<italic>Reviewer #1:</italic></p><p>The strengths of this paper include that it builds on previous research and its sample size. However, the calculation for the individual RBC turnover rate, k age, is not included. The calculation for the adjusted HbA1c is too unwieldy for the clinician to use in practice where there is increased pressure to see many patients on a timely basis. If a &quot;calculator&quot; could be formulated allowing the clinician to plug in the relevant values and get the adjusted HbA1c, this could be widely used to improve patient care at the point of care which is the ultimate goal of this research.</p><p>The author's claims of a proposed adjusted HbA1c which is more accurate in predicting adverse outcomes due to diabetes is supported by the data.</p><p>There is a model to estimate RBC lifespan using reticulocyte count: Brodsky, R. A. Diagnosis of hemolytic anemia in the adult. In J. S. Timauer (Ed.) UpToDate, Retrieved February 17, 2020 from https://www.uptodate.com/contents/diagnosis-of-hemolytic-anemia-in-the-adult?search=hemolytic%20anemia&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1.<italic>Reviewer #2:</italic></p><p>Laboratory HbA1c values are routinely used to assess glycemic control, but differences in red blood cell lifespan can affect hemoglobin glycation and HbA1c values. The authors developed a formula for adjusted HbA1c to account for red blood cell lifespan, which would better represent hemoglobin glycation and thus could better estimate the risk of disease complications.</p><p>The authors based their formula for aHbA1c calculation on laboratory measurements of HbA1c and CGM data performed with FreeStyle Libre. When using CGM systems, we often see falsified results for the duration of hypoglycemia, especially at night, due to sensor compression. The authors did not address these technical problems that may affect the aHbA1c result.</p><p>Using CGM we now have simple parameters to assess metabolic control of diabetes on the basis of CGM: TIR, GMI, CV. What I miss is a comparative analysis between these parameters and aHbA1c to convince readers that aHbA1c will be a better parameter for long term assessment for risk of complications.</p><p>The authors achieved their goal, and the results support their conclusions.</p><p>The use of aHbA1c in daily practice can be difficult because usually the clinician wants a ready result, but for research purposes, especially in patients with shorter red blood cell lifespans, it could be useful.</p><p>It will be interesting to see if its usefulness in estimating the risk of complications will be greater than TIR or GMI with CV.</p><p>Some comments on the methods and results:</p><p>Methods:</p><p>1. The study is based on CGM performed with FreeStyle Libre. From experience, we know that patients often have false hypoglycemia at night due to compression of the sensor. Has this been taken into account in the analysis?</p><p>2. Currently we use TIR and GMI to assess metabolic control in CGM users. Since aHbA1c, a new parameter will require additional calculations from me as a clinician, does it have advantages over these parameters in assessing the risk of chronic complications. It may be worth doing additional analysis comparing aHbA1c with these parameters.</p><p>3. As this is proof of concept, the details of creating the equation should be described, probably in some supplement. In addition, the idea behind the mathematical formula might help explain the equation to the readers. Secondly, the equation presented here is not clear in terms of units, and additionally operates slightly differently than the one in executed in provided excel file. The units for HbA1c here must be better emphasized. For example, if we assume HbA1c 9%, HbA1c in the numerator is treated as is (9%, % as a unit is preserved), but HbA1cs in the denominator have their units dropped (changed from 9% to 0.09). In parallel, the formula in excel does the same but multiplies the nominator by 100 (9% -&gt; 900 %) and leaves HbA1cs in the denominator as is (and 1 becomes 100%). This creates some confusion and should be better explained, or an example calculation could be shown.</p><p>Results:</p><p>1. I think, that any characteristics of this group in needed. They come from already-reported cohorts but this is only a subgroup, so some basic clinical characteristics (if available) would be welcome.</p><p>2. Ad Figure 2 May be it should be consider adding a scatter plot showing individual patients or HbA1c measurements. Or, for simplicity, mark how many patients (N, %) had their HbA1c adjusted by up to 1, 1-2, 2-3 and &gt;3%. This will provide a good estimate as to the range of applicability of your equation.</p><p><italic>Reviewer #3:</italic></p><p>The authors tried to adjust HbA1c to remove influence of erythrocyte lifespan. I admit the need for the adjustment, however, the study seems to lack the confirmation of their method.</p><p>1. The authors did not confirm the usefulness of their aHbA1c. The best way may be to confirm future diabetes complications as they mentioned, but it takes many years. I recommend to compare aHbA1c and average glucose derived by CGM.</p><p>2. The method requires complicated calculation from CGM data. I am not sure if the method is better than the simple average glucose derived CGM. Maybe, the kinetic method does not require steady state.</p><p>3. The value of k<sub>gly</sub> was not stabilized; from 4.04E-6 to 9.95E-6. k<sub>gly</sub> is a constant of non-enzymic process. It was estimated to be 6-10E-6, but the most recent one was 7.0E-6 (Kameyama et al. 2021). The average value of 5.86E-6 is smaller than the previously estimated value. I think that this instability is attributable to the nature of the calculation asking both k<sub>gly</sub> and k<sub>age</sub>.</p><p>4. The value of HbA1c should be converted to IFCC value.</p><p>&quot;While the National Glycohemoglobin Standardization Program (NGSP) is used to express HbA1c in many clinical research and medical care settings, NGSP is measured by an old standardized method and at the time of conception, HPLC was not able to distinguish true HbA1c from other products. HPLC technology later advanced, however the derived HbA1c value is adjusted to NGSP in the interest of consistency. IFCC provides a strict definition of iA1c as hemoglobin with a glycated valine in the N-terminal β-chain. Thus, iA1c value is preferred value for estimation of hemoglobin glycation.&quot; (Kameyama et al., 2021)</p><p>5. The authors chose random destruction model of erythrocytes, however &quot;unlike some other species including mice, all normal human RBCs have about the same lifespan and thus exhibit non-random removal ( Franco, 2009 ).&quot; Kameyama et al., (2018) provided erythrocyte model based on Γ-distribution by Shrestha et al., (2016). Program Modification from random destruction model to the uniform distribution of RBC ages model (Γmodel requires 2 parameters, so model that every RBC dies at the same age would be better to program) may be troublesome, but I think it is worth.</p><p>6. Equation 1 needs the derivation. i.e. d HbA1c/dt = 0; -k<sub>age</sub> HbA1c + k<sub>gly</sub> AG(1-HbA1c) = 0, -k<sub>age</sub><sup>ref</sup> HbA1c + k<sub>gly</sub> AG(1-HbA1c) = 0</p><p>Kameyama M, et al., Estimation of the hemoglobin glycation rate constant. Sci Rep. 2021 Jan 13;11(1):986. doi: 10.1038/s41598-020-80024-7.</p><p>Franco RS. The measurement and importance of red cell survival. Am J Hematol. 2009 Feb;84(2):109-14. doi: 10.1002/ajh.21298.</p><p>Kameyama M, Takeuchi S, Ishii S. Steady-state relationship between average glucose, HbA1c and RBC lifespan. J Theor Biol. 2018 Jun 14;447:111-117. doi: 10.1016/j.jtbi.2018.03.023.</p><p>Shrestha RP et al. Models for the red blood cell lifespan. J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):259-74. doi: 10.1007/s10928-016-9470-4.</p><p>I think that the merit of the author's method is to obtain the erythrocyte lifespan. It would be interesting to compare mean erythrocyte age by Kameyama's equation (M<sub>rbc</sub> = HbA1c / ((1-(2/3)HbA1c)k<sub>g</sub> AG)) and k<sub>age</sub>.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.69456.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) A more complete description of the derivation of the model – more detail is required as to how the computations were done.</p></disp-quote><p>As requested, we now provide further details on model derivation and validation. The additional details have been added to the main text and supplementary materials. More specifically, the following items have been added:</p><p>1. Derivation of the model and equation (1) (supplementary materials).</p><p>Please see under “Derivation of equation (1): kinetic model review”.</p><p>2. Kinetic parameter estimation (main text as below):</p><p>“Briefly, the model aligns laboratory HbA1c and the contemporaneous CGM-derived estimate of HbA1c under optimal values for RBC turnover and glucose uptake of each individual. Since there is no simple clinical assay for RBC turnover and glucose uptake, these RBC parameters are estimated using a numerical method such that differences between laboratory HbA1c and CGM-derived estimate are minimized. While parameter identification method can be performed by repeated permutations across all reasonably possible values for RBC lifespan and uptake, our approach uses a far more efficient and reliable numerical method, as previously described [9]. Detailed model description and derivation are provided in the supplementary materials.”</p><p>3. Using data from various cohorts, including different ages (paediatric, adult, old), populations (UK, DE, JP) and devices (Abbott, Medtronic), we further validate the model and compare with GMI (Table S1 added to supplementary material).</p><disp-quote content-type="editor-comment"><p>2) A comparison to other methods of assessing glycemic control (CGM, A1c). While assessment of how the authors' model predicts complications will not be required, a comparison (or at the very least, detailed discussion) of how it can compare to standard means of assessing glycemic control is necessary.</p></disp-quote><p>We have added to the Discussion and Supplementary material the differences, advantages and disadvantages of using different average glycemic measures for the management of individuals with diabetes with a summary table (Table S2).</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>The strengths of this paper include that it builds on previous research and its sample size. However, the calculation for the individual RBC turnover rate, k age , is not included. The calculation for the adjusted HbA1c is too unwieldy for the clinician to use in practice where there is increased pressure to see many patients on a timely basis. If a &quot;calculator&quot; could be formulated allowing the clinician to plug in the relevant values and get the adjusted HbA1c, this could be widely used to improve patient care at the point of care which is the ultimate goal of this research.</p></disp-quote><p>We would like to thank the reviewer for this pragmatic suggestion. Our model provides a method to calculate RBC lifespan from glucose and HbA<sub>1c</sub> data. The optimization algorithm requires powerful software, inclusion of large data sets and complex calculations to accurately derive aHbA<sub>1c</sub>, hindering current use in routine clinical practice. However, it is envisaged that the software will be included in future CGM devices, which will be able to automatically calculate aHbA<sub>1c</sub> once provided the necessary HbA<sub>1c</sub> and CGM data.</p><p>To satisfy the reviewer, we do provide a simplified approach to calculate approximate aHbA<sub>1c</sub> that can be provisionally used in clinical practice, provided there is access to high quality CGM data and two laboratory HbA<sub>1c</sub> measurements. In following steps, the RBC turnover rate may be estimated from glucose and HbA<sub>1c</sub> data in the supplementary materials, based on the previous publication [9].</p><p>1. For each data sections that contains a CGM trace and beginning and ending HbA<sub>1c</sub> values, a series of daily average glucose are computed.</p><p>2. Feed the daily average glucose series to equation (s9) and perform a search for optimal parameter pair of k<sub>gly</sub> and k<sub>age</sub> that A1c<sub>Z</sub> values best agree with lab values in all data sections available. Once k<sub>age</sub> is available, equation (1) can be used to provide adjusted HbA<sub>1c</sub>. The RBC lifespan can be estimated roughly from reticulocyte count as pointed out by the reviewer:</p><p>RBC lifespan (days) ≈ 100 ÷ [Reticulocytes (percent) ÷ RLS (days)]</p><p>The reticulocyte life span (RLS) is 1.0, 1.5, 2.0, or 2.5 days at hematocrits of 45, 35, 25, and 15 percent, respectively. It can also be estimated by other measurements such as erythrocyte creatine, RDW.</p><disp-quote content-type="editor-comment"><p>The author's claims of a proposed adjusted HbA1c which is more accurate in predicting adverse outcomes due to diabetes is supported by the data.</p></disp-quote><p>Thank you for the comment, in the manuscript we state that this model has the potential to provide a more accurate measure of future diabetes complications but future large scale longitudinal studies are required to assess the clinical role of adjusted HbA<sub>1c</sub>.</p><disp-quote content-type="editor-comment"><p>There is a model to estimate RBC lifespan using reticulocyte count: Brodsky, R. A. Diagnosis of hemolytic anemia in the adult. In J. S. Timauer (Ed.) UpToDate, Retrieved February 17, 2020 from https://www.uptodate.com/contents/diagnosis-of-hemolytic-anemia-in-the-adult?search=hemolytic%20anemia&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1</p></disp-quote><p>We would like to thank the reviewer for this helpful suggestion. We are aware of the method estimating RBC lifespan using reticulocyte count but it has a number of drawbacks making it difficult to implement. First, it is a crude calculation of RBC lifespan and therefore the data generated are unlikely to be sensitive to small physiological changes in this parameter, encountered between different individuals. Second, it relies on steady state, indicating the need to take average of several measurements, adding difficulties to data collection and interpretation. Third, it requires repeated reticulocyte data, which are not usually performed in routine clinical practice.</p><p>We would have liked to analyse the role of incorporating reticulocytes into the model but we do not have the necessary data to undertake the work. We are evaluating multiple ways of estimating RBC lifespan and glucose uptake rate (added reference [20] in discussion) and will certainly consider adding reticulocyte count as an additional measure to investigate whether this improves the accuracy of the model.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>Laboratory HbA1c values are routinely used to assess glycemic control, but differences in red blood cell lifespan can affect hemoglobin glycation and HbA1c values. The authors developed a formula for adjusted HbA1c to account for red blood cell lifespan, which would better represent hemoglobin glycation and thus could better estimate the risk of disease complications.</p><p>The authors based their formula for aHbA1c calculation on laboratory measurements of HbA1c and CGM data performed with FreeStyle Libre. When using CGM systems, we often see falsified results for the duration of hypoglycemia, especially at night, due to sensor compression. The authors did not address these technical problems that may affect the aHbA1c result.</p></disp-quote><p>The results should be sensor independent as evidenced by a published validation using Medtronic sensor data [17]. The calculation depends on series of daily average glucose between HbA<sub>1c</sub> measurements. The night-time low readings (due to compression or other artefacts) are usually short and should have a minimal effect on daily average glucose, particularly when large sets of data are collected.</p><p>In order to evaluate further, we divided CGM data into tertiles of hypoglycemic exposure (defined as glucose &lt;54 mg/dl) during the period of 11PM – 6AM. The model validation was done by first calculating individual k<sub>gly</sub> and k<sub>age</sub> with the first data section and project HbA1c on the second held-out section. We validated the model by comparing the final lab HbA1c and CGM-derived HbA1c. The mean ± SD of the absolute deviation in CGM-derived HbA1c and lab HbA1c (NGSP %) in the lowest hypoglycemic tertile (0-1% or 0-4 mins/night) was 0.32±0.22, middle tertile (1-4% or 4-17 mins/night) was 0.32±0.20, and highest tertile (4-12% or 17-50 mins/night) was 0.30±0.23, showing no difference (p&gt;0.1). Therefore, we conclude that nocturnal hypoglycemic events, whether true or artificial due to sensor compression, do not affect the accuracy of the kinetic model calculation.</p><disp-quote content-type="editor-comment"><p>Using CGM we now have simple parameters to assess metabolic control of diabetes on the basis of CGM: TIR, GMI, CV. What I miss is a comparative analysis between these parameters and aHbA1c to convince readers that aHbA1c will be a better parameter for long term assessment for risk of complications.</p></disp-quote><p>Thank you for raising this point; aHbA<sub>1c</sub> is an intracellular marker of glycation and thus likely more relevant to diabetes complications that TIR or GMI, which are simply based on plasma glucose levels. We elaborated further in the discussion to clarify this point:</p><p>“As a intracellular marker, aHbA<sub>1c</sub> should correlate with intracellular glucose levels, therefore providing a potentially accurate measure of glucose exposure of organs susceptible to diabetes complications”</p><p>and also added Table S2 comparing aHbA<sub>1c</sub> with other average glycemic measures (please see above).</p><disp-quote content-type="editor-comment"><p>The authors achieved their goal, and the results support their conclusions.</p><p>The use of aHbA1c in daily practice can be difficult because usually the clinician wants a ready result, but for research purposes, especially in patients with shorter red blood cell lifespans, it could be useful.</p></disp-quote><p>We would like to thank the reviewer for these positive comments.</p><disp-quote content-type="editor-comment"><p>It will be interesting to see if its usefulness in estimating the risk of complications will be greater than TIR or GMI with CV.</p></disp-quote><p>In theory, aHbA<sub>1c</sub> should predict complication risk better than HbA<sub>1c</sub>, or other glycemic markers, by better reflecting intracellular glucose exposure in organs prone to diabetes complications. However, we fully agree with the reviewer that longitudinal studies are required to assess the potential superiority of aHbA<sub>1c</sub> over other glycaemic markers and this will be part of our long-term strategy.</p><disp-quote content-type="editor-comment"><p>Some comments on the methods and results:</p><p>Methods:</p><p>1. The study is based on CGM performed with FreeStyle Libre. From experience, we know that patients often have false hypoglycemia at night due to compression of the sensor. Has this been taken into account in the analysis?</p></disp-quote><p>Please see our response above.</p><disp-quote content-type="editor-comment"><p>2. Currently we use TIR and GMI to assess metabolic control in CGM users. Since aHbA1c, a new parameter will require additional calculations from me as a clinician, does it have advantages over these parameters in assessing the risk of chronic complications. It may be worth doing additional analysis comparing aHbA1c with these parameters.</p></disp-quote><p>aHbA<sub>1c</sub> should reflect intracellular glucose exposure in organs prone to diabetes complications and our data suggests it would be superior to HbA<sub>1c</sub>, which assesses RBC intracellular glucose exposure but fails to take into account potential artefacts generated by altered RBC lifespan. Also, aHbA<sub>1c</sub> is potentially a better marker of future complication risk than average plasma extracellular glucose estimations such as TIR and GMI, which fail to take into account intracellular glucose exposure. However, large-scale longitudinal will be required to prove that aHbA<sub>1c</sub> is a superior marker of diabetes complications and this is our long-term aim. We expanded the discussion to cover the above points and also added a Table addressing differences between aHbA<sub>1c</sub> and GMI in relation to HbA<sub>1c</sub> (please see response to comments above).</p><disp-quote content-type="editor-comment"><p>3. As this is proof of concept, the details of creating the equation should be described, probably in some supplement. In addition, the idea behind the mathematical formula might help explain the equation to the readers. Secondly, the equation presented here is not clear in terms of units, and additionally operates slightly differently than the one in executed in provided excel file. The units for HbA1c here must be better emphasized. For example, if we assume HbA1c 9%, HbA1c in the numerator is treated as is (9%, % as a unit is preserved), but HbA1cs in the denominator have their units dropped (changed from 9% to 0.09). In parallel, the formula in excel does the same but multiplies the nominator by 100 (9% -&gt; 900 %) and leaves HbA1cs in the denominator as is (and 1 becomes 100%). This creates some confusion and should be better explained, or an example calculation could be shown.</p></disp-quote><p>We have added further clarifications as requested by the reviewer:</p><p>“HbA<sub>1c</sub> and aHbA<sub>1c</sub> are in NGSP unit and decimal values should be used. For example, 8% HbA1c should be applied as 0.08. Equation 1 for IFCC unit is available in the supplementary materials.”</p><disp-quote content-type="editor-comment"><p>Results:</p><p>1. I think, that any characteristics of this group in needed. They come from already-reported cohorts but this is only a subgroup, so some basic clinical characteristics (if available) would be welcome.</p></disp-quote><p>Basic characteristics of the groups have been added as requested in Table 1.</p><disp-quote content-type="editor-comment"><p>2. Ad Figure 2 May be it should be consider adding a scatter plot showing individual patients or HbA1c measurements. Or, for simplicity, mark how many patients (N, %) had their HbA1c adjusted by up to 1, 1-2, 2-3 and &gt;3%. This will provide a good estimate as to the range of applicability of your equation.</p></disp-quote><p>This has been done as requested:</p><p>“The number (percentage) of individuals having HbA1c adjustments &lt; 1% (&lt;11mmol/mol), 1-2% (11-22 mmol/mol), 2-3% (22-33 mmol/mol) and &gt;3% (&gt;33 mmol/mol) were 90 (68%), 21 (16%), 12 (9%), and 8 (6%), respectively.”</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>The authors tried to adjust HbA1c to remove influence of erythrocyte lifespan. I admit the need for the adjustment, however, the study seems to lack the confirmation of their method.</p><p>1. The authors did not confirm the usefulness of their aHbA1c. The best way may be to confirm future diabetes complications as they mentioned, but it takes many years. I recommend to compare aHbA1c and average glucose derived by CGM.</p></disp-quote><p>Based on the Brownlee’s work [reference 5], it is the high intracellular glucose exposure that is the main cause of tissue damage and diabetes complications. However, average glucose levels do not necessarily reflect intracellular glucose exposure. Therefore, adjusted HbA<sub>1c</sub>, which reflects intracellular glycemia, is difficult to compare with average glucose (extracellular) and HbA<sub>1c</sub> (affected by RBC lifespan). We added this to the discussion and also added Table S2 to summarise strengths and drawbacks of different average glycaemic measures.</p><disp-quote content-type="editor-comment"><p>2. The method requires complicated calculation from CGM data. I am not sure if the method is better than the simple average glucose derived CGM. Maybe, the kinetic method does not require steady state.</p></disp-quote><p>The kinetic parameter determination (for k<sub>gly</sub> and k<sub>age</sub>) does not require a steady state. Please refer to the first answer in reviewer #1 for more details on determining kinetic parameters. The kinetic model relies on data from CGM-derived glucose levels and laboratory HbA<sub>1c</sub>. We demonstrated superior accuracy of the kinetic model compared with the average glucose derived HbA1c (GMI) in the supplementary material (Table S1). The parameter k<sub>age</sub> (or RBC lifespan) need to be determined before adjusted HbA<sub>1c</sub> can be calculated. Again, adjusted HbA<sub>1c</sub> is an intracellular marker, while average glucose is not. This would be particularly relevant in individuals with apparent high laboratory HbA<sub>1c</sub> and repeated hypoglycaemia or in those with low HbA<sub>1c</sub> but high average glucose.</p><disp-quote content-type="editor-comment"><p>3. The value of k<sub>gly</sub> was not stabilized; from 4.04E-6 to 9.95E-6. k<sub>gly</sub> is a constant of non-enzymic process. It was estimated to be 6-10E-6, but the most recent one was 7.0E-6 (Kameyama et al., 2021). The average value of 5.86E-6 is smaller than the previously estimated value. I think that this instability is attributable to the nature of the calculation asking both k<sub>gly</sub> and k<sub>age</sub>.</p></disp-quote><p>Although hemoglobin glycation is a non-enzymatic reaction with constant rate parameters, the reaction is limited by intracellular glucose levels rather than plasma glucose. According to Khera [7], RBC glucose uptake rate or intra/extracellular glucose concentration ratio varies person to person. For this reason, k<sub>gly</sub>, the overall glycation rate constant, should be an individual kinetic parameter, which explains various k<sub>gly</sub> values reported in the literature. We highlight this in supplementary materials, summarizing our first publication of the model.</p><disp-quote content-type="editor-comment"><p>4. The value of HbA1c should be converted to IFCC value.</p><p>&quot;While the National Glycohemoglobin Standardization Program (NGSP) is used to express HbA1c in many clinical research and medical care settings, NGSP is measured by an old standardized method and at the time of conception, HPLC was not able to distinguish true HbA1c from other products. HPLC technology later advanced, however the derived HbA1c value is adjusted to NGSP in the interest of consistency. IFCC provides a strict definition of iA1c as hemoglobin with a glycated valine in the N-terminal β-chain. Thus, iA1c value is preferred value for estimation of hemoglobin glycation.&quot; (Kameyama et al., 2021)</p></disp-quote><p>Thank you for raising this topic. We added equation (1) under NGSP unit system in the supplementary materials.</p><disp-quote content-type="editor-comment"><p>5. The authors chose random destruction model of erythrocytes, however &quot;unlike some other species including mice, all normal human RBCs have about the same lifespan and thus exhibit non-random removal ( Franco, 2009 ).&quot; Kameyama et al., (2018) provided erythrocyte model based on Γ-distribution by Shrestha et al., (2016). Program Modification from random destruction model to the uniform distribution of RBC ages model (Γmodel requires 2 parameters, so model that every RBC dies at the same age would be better to program) may be troublesome, but I think it is worth.</p></disp-quote><p>Thank you for the helpful comment and for bringing new references to our attention.</p><p>The derivation starts with uniform age distribution or fixed-life model for RBC lifespan as suggested. We added the details to the supplementary materials. The additional complexity brought by glucose uptake following GLUT1 Michaelis-Menten kinetics and the approximations used has led to the steady-state equation (1). These approximations enable a robust application to real-world, non-steady state conditions. We have shown this reflects real world data well, given the accuracy of our validation studies [references 9, 17, 18]. We demonstrate below steady-state solution from a strict uniform age distribution, further confirming robustness of the model.</p><p>The steady-state equation (1) under the uniform age distribution is:</p><p>The circulating RBCs are produced within the last L days, where L is the expected lifespan. No RBC was lost until age&gt;L. For a small fraction of RBC of age=t, where t&lt;L:</p><p><inline-formula><mml:math id="sa2m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mtext>hBg</mml:mtext><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:mi>G</mml:mi><mml:mi>I</mml:mi><mml:mo>∗</mml:mo><mml:mi>C</mml:mi><mml:mo>∗</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:mtext>dt</mml:mtext><mml:mi>L</mml:mi></mml:mfrac><mml:mo>∗</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula>where C is total hemoglobin (C = <italic>Hb</italic> + <italic>HbG</italic>)</p><p>Therefore, the total glycated hemoglobin is:</p><p><inline-formula><mml:math id="sa2m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>G</mml:mi><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:msubsup><mml:mo>∫</mml:mo><mml:mrow><mml:mi>O</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:mi>G</mml:mi><mml:mi>I</mml:mi><mml:mo>∗</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:mi>C</mml:mi><mml:mi>L</mml:mi></mml:mfrac><mml:mo>∗</mml:mo><mml:mi>t</mml:mi><mml:mo>∗</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:mi>L</mml:mi><mml:mo>∗</mml:mo><mml:mi>G</mml:mi><mml:mi>I</mml:mi><mml:mo>∗</mml:mo><mml:mi>C</mml:mi><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mn>2</mml:mn><mml:mo>∗</mml:mo><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow></mml:msub></mml:mfrac><mml:mo>∗</mml:mo><mml:mi>G</mml:mi><mml:mi>I</mml:mi><mml:mo>∗</mml:mo><mml:mi>C</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>Where,<inline-formula><mml:math id="sa2m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:mn>1</mml:mn><mml:mi>L</mml:mi></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula></p><p>Since <inline-formula><mml:math id="sa2m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>H</mml:mi><mml:mtext>bA</mml:mtext><mml:mn>1</mml:mn><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:mtext>HbG</mml:mtext><mml:mi>C</mml:mi></mml:mfrac></mml:mrow></mml:mstyle></mml:math></inline-formula>, steady state<inline-formula><mml:math id="sa2m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi><mml:mo>:</mml:mo><mml:mtext> </mml:mtext><mml:mtext>EA</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mn>2</mml:mn><mml:mo>∗</mml:mo><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow></mml:msub></mml:mfrac><mml:mo>∗</mml:mo><mml:mi>G</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula></p><p>Equation (1) is about finding HbA1c under a reference k<sub>age</sub> with the same intracellular glucose level. Therefore, the HbA1c with equivalent intracellular glucose under a reference <inline-formula><mml:math id="sa2m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mtext>GI</mml:mtext><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:msub><mml:mtext>GI</mml:mtext><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow><mml:mrow><mml:mtext>ref</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula> is:<inline-formula><mml:math id="sa2m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:msub><mml:mtext>EA</mml:mtext><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow><mml:mrow><mml:mtext>ref</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow></mml:msub><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow><mml:mrow><mml:mtext>ref</mml:mtext></mml:mrow></mml:msubsup></mml:mfrac><mml:mo>∗</mml:mo><mml:mtext> </mml:mtext><mml:msub><mml:mtext>EA</mml:mtext><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> equation (1) becomes:<disp-formula id="sa2equ1"><label>equation (1f)</label><mml:math id="sa2m8"><mml:mrow><mml:mi>A</mml:mi><mml:mi>h</mml:mi><mml:mi>B</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow></mml:msub><mml:msubsup><mml:mi>k</mml:mi><mml:mrow><mml:mtext>age</mml:mtext></mml:mrow><mml:mrow><mml:mtext>ref</mml:mtext></mml:mrow></mml:msubsup></mml:mfrac><mml:mo>∗</mml:mo><mml:mi>H</mml:mi><mml:mi>b</mml:mi><mml:mi>A</mml:mi><mml:mn>1</mml:mn><mml:mi>c</mml:mi></mml:mrow></mml:math></disp-formula></p><p>This function is very close to equation (1) numerically. Note that equation (1f) is an approximation form of equation (1). In general, the differences between equation (1) and (1f) are less than 0.25% (NGSP) within +/- 20% change of RBC lifespan and HbA1c range of 5-10% (NGSP).</p><disp-quote content-type="editor-comment"><p>6. Equation 1 needs the derivation. i.e. d HbA1c/dt = 0; -k<sub>age</sub> HbA1c + k<sub>gly</sub> AG(1-HbA1c) = 0, -k<sub>age</sub><sup>ref</sup> HbA1c + k<sub>gly</sub> AG(1-HbA1c) = 0</p><p>Kameyama M, et al. Estimation of the hemoglobin glycation rate constant. Sci Rep. 2021 Jan 13;11(1):986. doi: 10.1038/s41598-020-80024-7.</p><p>Franco RS. The measurement and importance of red cell survival. Am J Hematol. 2009 Feb;84(2):109-14. doi: 10.1002/ajh.21298.</p><p>Kameyama M, Takeuchi S, Ishii S. Steady-state relationship between average glucose, HbA1c and RBC lifespan. J Theor Biol. 2018 Jun 14;447:111-117. doi: 10.1016/j.jtbi.2018.03.023.</p><p>Shrestha RP et al. Models for the red blood cell lifespan. J Pharmacokinet Pharmacodyn. 2016 Jun;43(3):259-74. doi: 10.1007/s10928-016-9470-4.</p></disp-quote><p>Thank you for the new references, the majority of which have been incorporated into the current version of the manuscript. Please refer to our reply to essential revision (1) and additional supplementary materials for the derivation of equation 1.</p><disp-quote content-type="editor-comment"><p>I think that the merit of the author's method is to obtain the erythrocyte lifespan. It would be interesting to compare mean erythrocyte age by Kameyama's equation (M<sub>rbc</sub> = HbA1c / ((1-(2/3)HbA1c)k<sub>g</sub> AG)) and k<sub>age</sub>.</p></disp-quote><p>Future work is required for developing practical and robust methods that accurately measure RBC lifespan. Comparing to Kameyama's equation which has a universal glucose uptake (k<sub>gly</sub>), our model evaluates k<sub>gly</sub> as individual-specific variable. Therefore, it is problematic to compare the two methods directly by k<sub>age</sub> and M<sub>RBC</sub>. However, the ratio k<sub>gly</sub>/k<sub>age</sub> may be comparable with M<sub>RBC</sub> as per Kameyama’s work. While taking this caveat into account, we investigated the relationship between M<sub>RBC</sub> and K and found a positive correlation (R=0.62, p&lt;0.0001), providing additional evidence to support of our model.</p></body></sub-article></article>